<DOC>
	<DOC>NCT01242098</DOC>
	<brief_summary>The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.</brief_summary>
	<brief_title>Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Aged: 1860 years: 6180 years who are neversmokers Evidence of asthma: a diagnostic code for asthma, or ≥2 prescriptions for asthma at different points in time during the prior year Baseline FP/SAL therapy: ≥2 prescription for ICS/LABA therapy as FP/SAL (Seretide® 125). Any chronic respiratory disease other than asthma Are receiving maintenance oral steroid therapy during baseline period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Primary care management</keyword>
	<keyword>Switch</keyword>
	<keyword>ICS/LABA</keyword>
	<keyword>Fostair</keyword>
	<keyword>Seretide</keyword>
</DOC>